Aby J. Mathew - Apr 19, 2023 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
EVP & Chief Scientific Officer
Signature
/s/ Aby J. Mathew
Stock symbol
BLFS
Transactions as of
Apr 19, 2023
Transactions value $
-$346,000
Form type
4
Date filed
4/21/2023, 07:00 PM
Previous filing
Apr 10, 2023
Next filing
May 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $20.6K +10K +3.73% $2.06* 278K Apr 19, 2023 Direct
transaction BLFS Common Stock Sale -$195K -10K -3.59% $19.47 268K Apr 19, 2023 Direct F1, F2
transaction BLFS Common Stock Options Exercise $20.6K +10K +3.73% $2.06* 278K Apr 20, 2023 Direct
transaction BLFS Common Stock Sale -$193K -10K -3.59% $19.25 268K Apr 20, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -10K -7.69% $0.00 120K Apr 19, 2023 Common Stock 10K $2.06 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -10K -8.33% $0.00 110K Apr 20, 2023 Common Stock 10K $2.06 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 11-15-2022
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.31 to $19.57, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $19.50, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.